Open in interactive viewer → charts, metric popovers & call review

Novanta’s Perfect Storm Is a Factory, Not a Demand Problem

Record margins, a sold-out spindle franchise and a $543M backlog ran into a self-inflicted Q4 gross-margin reset—and a stock already 27% below its August peak.
NOVT · Earnings Call · 2026-11-10

The beat that couldn’t lift the stock

Novanta’s third quarter was, on the face of it, a blowout. Revenue rose 23% to $305 million, organic growth was nearly 10%, adjusted EBITDA grew 38% to $80 million for a record 26% margin, and adjusted EPS rose 21% to $1.05. Bookings grew 29%, book-to-bill was 1.08, and backlog ended at $543 million with core backlog up 14%. The Medical Solutions segment grew 30% reported and about 3% organic, while advanced surgical technologies grew 66% reported and 12% organic. Management called it the strongest strategic and financial position in more than a decade. The stock disagreed. NOVT is down 16.3% over the last 90 trading days and 26.7% from its August 17 peak. Some of that is sector beta: the global tape has been punishing the AI infrastructure complex, with AI data centers among the 30-day decliners. But the company-specific reason is in the fourth-quarter guide. Revenue is guided to $306 million-$312 million, organic growth of 5%-7%, adjusted EBITDA of $76 million-$79 million, and adjusted EPS of $0.91-$0.96. The full-year adjusted gross margin is now expected at about 46.5%, and the Q4 margin is guided to roughly 46%—not the 48% management had been signaling.

What actually broke: Stockport and the cost of consolidation

The culprit is a single U.K. factory. At Stockport, a major end user found an issue in testing, and Novanta stopped shipping while it corrects the problem. The program is not lost; shipments are expected to restart in the first quarter. But the timing collides with the company’s multiyear manufacturing consolidation, which is already carrying redundant factory costs as two factories move into the site.

Yes, let me just add to that you have somewhat of a perfect storm happening there. You do have redundant costs because we are moving two factories into that location... There's roughly a 200 basis point impact as a consequence of this, so we're reporting something closer to 46% in the fourth quarter. It should be 48%.

Robert Buckley, Chief Financial Officer · 2026-11-10
That is the tension. Management frames this as a temporary headwind, and the CEO was explicit: “The program is not in jeopardy. The customer wants this product.” — Matthijs Glastra, Chair and Chief Executive Officer · 2026-11-10 But the “temporary” label has a history. On the August call, the CFO had already promised the back half would run near 48% and that 2027 would add another 100 basis points: “We delivered a 47% gross margin in the second quarter. We're looking at something closer to 48% in the back half of the year. And I would expect that to maintain into 2027. So we're looking at another 100 basis points of improvement in 2027.” — Robert Buckley, Chief Financial Officer · 2026-08-06 Now the full-year number is 46.5%, and the fourth quarter is 46%. The 2027 target still exists—management reiterated at least 100 basis points of gross-margin expansion—but it now depends on a Q1 restart and a Q2 bounce. And redundant manufacturing costs are not a one-off; they have been a recurring feature of the site-consolidation story. A year ago, the CFO described the regional manufacturing program as worth “roughly about 100 basis points of incremental margin expansion” even after duplication. “it's roughly about 100 basis points of incremental margin expansion despite the fact that a traditional regional manufacturing initiative would result in duplication of manufacturing and duplication of cost structure.” — Robert Buckley, Chief Financial Officer · 2025-11-04 The market has heard this before.

The demand engine underneath

What makes the reset frustrating is that underlying demand looks stronger than it has in years. Three of four business units grew organically. New product revenue rose 23% in the quarter and 47% year to date, lifting the vitality index to about 27% of sales. Incremental design wins rose 63%. The air bearing spindle business—the mechanical drilling niche that benefits from thick GPU boards—is sold out. Chuck Ravetto put it plainly: “Our air bearing spindles business, which serves the mechanical drilling of electronics, is sold out for the next two years, and we expect to double the business over that period.” — Charles Ravetto, Unknown · 2026-11-10 The China expansion is on track for the end of this year, with full ramp by April 2027. That is a company-unique bottleneck, not a generic AI narrative. There is also a broader semiconductor-equipment read-through. Demand for packaging substrates and advanced packaging is pulling through laser beam steering and motion subsystems. In medical, Riverpoint Medical contributed $33 million in its first two months and moves recurring consumables to roughly 25% of revenue. John Lesica framed the runway: “Riverpoint moves recurring medical consumables to roughly 25% of Novanta's revenue, and we currently address only about 10% of the minimally invasive surgical consumables market.” — John Lesica, Unknown · 2026-11-10 The sports medicine knotless sutures launched with three leading OEMs, and servo drives and medical robotics content is expanding. This is the “more medical, more recurring, less cyclical” story management has been telling, and the numbers support it. The offset is precision medicine, where sales fell 5% as expected after a strategic decision to walk away from lower-margin business tied to a research-spending-constrained customer. Life sciences is now less than 10% of revenue, and management does not expect that business to grow again until late 2027. That is a drag, but a contained one.

Why it matters

Novanta is not cheap enough to shrug off another execution slip. The latest filed fundamentals—period ended July 29, before the Q3 call—show a 5.6x price-to-revenue multiple and a 72.5x price-to-free-cash-flow multiple. The balance sheet is manageable: net debt of $689 million and net leverage of 2.2x after the $1.2 billion Riverpoint deal, with management prioritizing deleveraging. The 2027 framework—more than 15% reported revenue growth and more than 20% adjusted EBITDA growth—is intact. If Stockport restarts in Q1 and gross margin snaps back toward 48% by Q2, the current drawdown may look like an execution-risk discount rather than a broken thesis. If it slips again, the market will have learned that “temporary” is a word Novanta uses loosely. The next two quarters are a prove-it window: the Stockport restart, the air-spindle capacity ramp, and the Riverpoint integration all need to land. The demand is there. The factory is the question.